{
  "company_name": "Ontex Group NV",
  "legal_entity": "Ontex Group SA/NV",
  "alternate_names": [
    "Ontex Group",
    "Ontex NV"
  ],
  "sector": "Consumer & Retail - Personal Hygiene Products",
  "geography": "Belgium",
  "last_updated": "2026-01-21",
  "data_source": "Debtwire",
  "ratings": {
    "moodys": {
      "rating": "NR",
      "outlook": null
    },
    "sp": {
      "rating": "B+",
      "outlook": "Stable"
    },
    "note": "S&P revised outlook to Stable from Positive (Jan 2025) after FY25 guidance cut"
  },
  "overview": {
    "business_description": "Belgian manufacturer of personal hygiene products including baby diapers, feminine care products, and adult incontinence products. Sells through retail private label and healthcare channels across Europe and emerging markets.",
    "business_positives": [
      "Low distress score of 8 - performing credit",
      "Conservative leverage at 2.77x Net Debt/EBITDA",
      "Stable end markets (essential consumer products)",
      "Strong CFFO of $107m LTM",
      "Publicly traded with $493m market cap equity cushion",
      "European market leader in private label hygiene"
    ],
    "fatal_flaw": "EBITDA declining (-17% FY24). FY25 outlook cut - now expecting further EBITDA decline. CEO transition and strategic review create uncertainty. Jul 2026 maturity approaching ($692m). Bond trading BELOW PAR at 98.34. Competitive market with P&G/Kimberly-Clark.",
    "ownership": "Public (Euronext Brussels: ONTEX). Diversified shareholder base.",
    "recent_news": "Cut FY25 EBITDA outlook (Jan 2025) - outlook revised to Stable from Positive. New CEO transition. Strategic review ongoing. Bond trading below par ahead of Jul 2026 maturity."
  },
  "quick_assessment": {
    "total_debt": 634,
    "cash_on_hand": 59,
    "revolver_available": null,
    "debt_due_one_year": 692,
    "cffo": 107,
    "interest_expense": null,
    "enterprise_value": 1128,
    "ebitda": 208,
    "market_cap": 493
  },
  "key_ratios": {
    "debt_to_ebitda": 3.05,
    "net_debt_to_ebitda": 2.77,
    "ev_to_ebitda": 5.4,
    "ebitda_margin": null,
    "ebitda_minus_capex_to_interest": null
  },
  "trend_analysis": {
    "years": [
      "FY 2022",
      "FY 2023",
      "FY 2024",
      "LTM Sep 2025"
    ],
    "ebitda": [
      182,
      251,
      208,
      208
    ],
    "total_debt": [
      794,
      628,
      635,
      634
    ],
    "gross_leverage": [
      4.4,
      2.5,
      3.1,
      3.1
    ],
    "net_leverage": [
      3.8,
      2.1,
      2.8,
      2.8
    ],
    "trend_summary": "EBITDA improved in 2023 but declined -17% in 2024. FY25 guidance cut signals further weakness. Leverage deteriorating from 2.5x back to 3.1x."
  },
  "debt_capitalization": [
    {
      "instrument": "EUR 400m Sr Secd Notes",
      "amount": 440,
      "maturity": "Jul 2026",
      "coupon": null,
      "price": 98.34,
      "ytw": null,
      "stw": null,
      "rating": "B+",
      "seniority": "Senior Secured",
      "trading_signal": "BELOW PAR - refinancing uncertainty"
    },
    {
      "instrument": "Other Secured Debt",
      "amount": 194,
      "maturity": null,
      "coupon": null,
      "price": null,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    }
  ],
  "maturity_schedule": {
    "year_1": 692,
    "year_2": 0,
    "year_3": 0,
    "year_4": 0,
    "year_5": 0,
    "thereafter": 0,
    "maturity_wall": "Jul 2026 - $692m needs refinancing"
  },
  "equity_market_value": {
    "ticker": "ONTEX.BR",
    "exchange": "Euronext Brussels",
    "equity_market_value": 493,
    "total_enterprise_value": 1128,
    "tev_to_ebitda": 5.4
  },
  "credit_opinion": {
    "recommendation": "NEUTRAL",
    "summary": "Ontex is a performing credit with low distress score (8) but faces near-term challenges. The Jul 2026 maturity wall ($692m) is approaching with bond trading below par (98.34), suggesting market concern about refinancing. EBITDA declined -17% in FY24 and FY25 guidance was cut, prompting S&P to revise outlook to Stable from Positive. CEO transition and strategic review add uncertainty. However, leverage at 2.77x is manageable and $493m market cap provides equity cushion. Essential consumer products provide stability but competitive pressure from P&G/Kimberly-Clark limits pricing power.",
    "key_risks": [
      "Jul 2026 maturity wall ($692m) - refinancing risk",
      "Bond below par (98.34) - market pricing uncertainty",
      "EBITDA declining - FY24 -17%, FY25 guidance cut",
      "CEO transition and strategic review uncertainty",
      "S&P outlook revised to Stable from Positive",
      "Competitive pressure from P&G, Kimberly-Clark",
      "Private label margin pressure",
      "Raw material cost volatility"
    ],
    "key_catalysts": [
      "Successful Jul 2026 refinancing",
      "EBITDA stabilization/recovery",
      "Strategic review outcome (asset sales, M&A)",
      "New CEO execution",
      "Rating upgrade if leverage maintained below 3.0x"
    ]
  },
  "distress_indicators": {
    "debtwire_distress_score": 8,
    "lifecycle_status": "Performing credit",
    "trading_signals": "Bond at 98.34 (BELOW PAR) despite low distress score. Market pricing Jul 2026 refinancing uncertainty. EBITDA declining. Watch for refinancing developments."
  },
  "watchlist_priority": "MEDIUM - Monitor Jul 2026 refinancing progress"
}